New combo aims to fight tough bladder cancer
NCT ID NCT03237780
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothelial cancer will take part. The goal is to see if the combination shrinks tumors more effectively and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope Upland
Upland, California, 91786, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Keck Medicine of USC Buena Park
Buena Park, California, 90621, United States
-
Keck Medicine of USC Koreatown
Los Angeles, California, 90020, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116, United States
-
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, 66211, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New strategy aims to eliminate residual bladder cancer after drug combo
- New hope for bladder cancer patients who Can't take chemo
- Experimental triple therapy for advanced cancers shows early promise but trial halted